Research and Markets: Biomarkers: Discovery Techniques and Applications - a Global Market Overview

DUBLIN--(BUSINESS WIRE)-- Research and Markets ( has announced the addition of the "Biomarkers: Discovery Techniques and Applications A Global Market Overview" report to their offering.

The proposed study covers the global market overview of Biomarkers with respect to discovery technologies including Bioinformatics, Genomics, Proteomics, Metabolomics etc., and the applications in therapeutic areas such as Oncology, Neurology, Cardiology etc. The regions covered in the report will comprise North America, Europe and Asia-Pacific.

The market data will be illustrated in the form of charts along with graphical representation. The key market players will be profiled from each of the regions. The report also includes the list of worldwide companies engaged in Biomarkers research, product development and supply and distribution.

The price is a pre-publication offer.

Key Topics Covered:


  • Introduction
  • Product Segmentation
  • Market Trends
  • Key Global Players
  • Key Business Trends
  • Key Product Trends
  • Global Market Overview


  • Regional Market Overview


  • This chapter includes the list of companies engaged in research, product/technology development of Biomarkers worldwide. The list covers the address, contact numbers and website addresses.


Companies Mentioned:

  • Abbott Laboratories
  • ACE BioSciences A/S
  • Affibody AB
  • Affymetrix, Inc
  • Agilent Technologies
  • Amgen
  • Applied Biosystems Group
  • Applied NeuroSolutions
  • AstraZeneca
  • AVIVA Biosciences Corporation
  • Bayer AG
  • Beckman Coulter, Inc
  • Becton, Dickinson and Company
  • BG Medicine Inc
  • Biacore International AB
  • Biocartis
  • BioMarker Pharmaceuticals, Inc
  • Bio-Rad Laboratories
  • Boehringer Ingelheim
  • Bristol-Myers Squibb Company
  • + many more

For more information visit


Research and Markets
Laura Wood, Senior Manager,
[email protected]
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716


INDUSTRY KEYWORDS:   Health  Biotechnology  Genetics



Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.